sRAGE and esRAGE are not Associated with Peripheral or Autonomic Neuropathy in Type 2 Diabetes

Abstract

The receptor for glycation end-products RAGE was previously shown to play a central role in the development of diabetic neuropathy. The present study was aimed to investigate, whether plasma levels of the soluble forms of RAGE are associated with neuropathy in type 2 diabetes. One-hundred and eight patients were screened for peripheral and autonomic diabetic neuropathy using standardized screening tests. No differences in the levels of soluble RAGE or the more defined endogenous secretory RAGE were observed in patients categorized into having no, mild, moderate, or severe deficits in the neuropathy disability or symptom score. In bivariate analysis, neither soluble RAGE nor endogenous secretory RAGE correlated with the expiration to inspiration ratio of heart rate variability. In multivariate models, the neuropathy disability score was independently associated with age (β=0.38, p<0.01), glomerular filtration rate (β=0.28, p<0.01) and the presence of retinopathy (β=0.27, p<0.01), while the neuropathy symptom score was associated with age (β=0.31, p<0.01) and fasting glucose (β=0.24, p<0.05). The expiration to inspiration ratio of heart rate variability was associated with age (β=-0.42, p<0.01), the body-mass-index (β=-0.28, p<0.01) and presence of retinopathy (β=-0.19, p<0.05). In contrast to classical risk factors, plasma soluble RAGE and endogenous secretory RAGE are not associated with measures of diabetic neuropathy in type 2 diabetes patients.

diabetic complications - microvascular - diabetic neuropathy - soluble RAGE - endogenous secretory RAGE

References

• 1 Geroldi D, Falcone C, Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target.  Curr Med Chem. 2006;  13 1971-1978
• 2 Nawroth P, Bierhaus A, Marrero M, Yamamoto H, Stern DM. Atherosclerosis and restenosis: is there a role for RAGE?.  Curr Diab Rep. 2005;  5 11-16
• 3 Wendt TM, Tanji N, Guo J. et al . RAGE drives the development of glomerulosclerosis and implicates podocyte activation in the pathogenesis of diabetic nephropathy.  Am J Pathol. 2003;  162 1123-1137
• 4 Sakurai S, Yamamoto Y, Tamei H. et al . Development of an ELISA for esRAGE and its application to type 1 diabetic patients.  Diabetes Res Clin Pract. 2006;  73 158-165
• 5 Bierhaus A, Haslbeck KM, Humpert PM. et al . Loss of pain perception in diabetes is dependent on a receptor of the immunoglobulin superfamily.  J Clin Invest. 2004;  114 1741-1751
• 6 Haslbeck KM, Schleicher E, Bierhaus A. et al . The AGE/RAGE/NF-(kappa)B pathway may contribute to the pathogenesis of polyneuropathy in impaired glucose tolerance (IGT).  Exp Clin Endocrinol Diabetes. 2005;  113 288-291
• 7 Humpert PM, Djuric Z, Kopf S. et al . Soluble RAGE but not endogenous secretory RAGE is associated with albuminuria in patients with type 2 diabetes.  Cardiovasc Diabetol. 2007;  6 9
• 8 Young MJ, Boulton AJ, MacLeod AF, Williams DR, Sonksen PH. A multicentre study of the prevalence of diabetic peripheral neuropathy in the United Kingdom hospital clinic population.  Diabetologia. 1993;  36 150-154
• 9 Humpert PM, Kopf S, Djuric Z. et al . Levels of three distinct p75 neurotrophin receptor forms found in human plasma are altered in type 2 diabetic patients.  Diabetologia. 2007;  50 1517-1522
• 10 Assessment: . Clinical autonomic testing report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.  Neurology. 1996;  46 873-880
• 11 Vincent AM, Perrone L, Sullivan KA. et al . Receptor for advanced glycation end products activation injures primary sensory neurons via oxidative stress.  Endocrinology. 2007;  148 548-558
• 12 Vinik AI, Park TS, Stansberry KB, Pittenger GL. Diabetic neuropathies.  Diabetologia. 2000;  43 957-973
• 13 Ziegler D, Zentai C, Perz S. et al . Selective contribution of diabetes and other cardiovascular risk factors to cardiac autonomic dysfunction in the general population.  Exp Clin Endocrinol Diabetes. 2006;  114 153-159
• 14 Humpert PM, Kopf S, Djuric Z. et al . Plasma sRAGE is independently associated with urinary albumin excretion in type 2 diabetes.  Diabetes Care. 2006;  29 1111-1113
• 15 Koyama H, Shoji T, Yokoyama H. et al . Plasma level of endogenous secretory rage is associated with components of the metabolic syndrome and atherosclerosis.  Arterioscler Thromb Vasc Biol. 2005;  25 2587-2593
• 16 Nakamura K, Yamagishi S, Adachi H. et al . Serum Levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.  Mol Med. 2007;  13 185-189
• 17 Nakamura K, Yamagishi S, Adachi H. et al . Elevation of soluble form of receptor for advanced glycation end products (sRAGE) in diabetic subjects with coronary artery disease.  Diabetes Metab Res Rev. 2007;  23 368-371
• 18 Cheng C, Tsuneyama K, Kominami R. et al . Expression profiling of endogenous secretory receptor for advanced glycation end products in human organs.  Mod Pathol. 2005;  18 1385-1396
• 19 Yonekura H, Yamamoto Y, Sakurai S. et al . Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury.  Biochem J. 2003;  370 1097-1109
• 20 Kasalova Z, Prazny M, Skrha J. Relationship between peripheral diabetic neuropathy and microvascular reactivity in patients with type 1 and type 2 diabetes mellitus - neuropathy and microcirculation in diabetes.  Exp Clin Endocrinol Diabetes. 2006;  114 52-57
• 21 Forsblom CM, Groop PH, Ekstrand A. et al . Predictors of progression from normoalbuminuria to microalbuminuria in NIDDM.  Diabetes Care. 1998;  21 1932-1938
• 22 Marre M, Lievre M, Chatellier G. et al . Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).  BMJ. 2004;  328 495
• 23 Bucciarelli LG, Wendt T, Qu W. et al . RAGE blockade stabilizes established atherosclerosis in diabetic apolipoprotein E-null mice.  Circulation. 2002;  106 2827-2835
• 24 Falcone C, Emanuele E, D'Angelo A. et al . Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men.  Arterioscler Thromb Vasc Biol. 2005;  25 1032-1037
• 25 Forbes JM, Thorpe SR, Thallas-Bonke V. et al . Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.  J Am Soc Nephrol. 2005;  16 2363-2372
• 26 Tan KC, Shiu SW, Chow WS. et al . Association between serum levels of soluble receptor for advanced glycation end products and circulating advanced glycation end products in type 2 diabetes.  Diabetologia. 2006;  49 2756-2762

Correspondence